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Abstract
Background: In about one third of all patients with cerebral ischemia, no definite cause can be
identified (cryptogenic stroke). In many patients with initially suspected cryptogenic stroke,
however, a cardiogenic etiology can eventually be determined. Hence, the aim of this study was to
describe the prevalence of abnormal echocardiographic findings in a large number of these patients.
Method: Patients with cryptogenic cerebral ischemia (ischemic stroke, IS, and transient ischemic
attack, TIA) were included. The initial work-up included a neurological examination, EEG, cCT,
cMRT, 12-lead ECG, Holter-ECG, Doppler ultrasound of the extracranial arteries, and
transthoracic echocardiography. A multiplane transeophageal echocardiography (TEE, including i.v.
contrast medium application [Echovist], Valsalva maneuver) was performed in all patients
Results: 702 consecutive patients (380 male, 383 IS, 319 TIA, age 18–90 years) were included. In
52.6% of all patients, TEE examination revealed relevant findings. Overall, the most common
findings in all patients were: patent foramen ovale (21.7%), previously undiagnosed valvular disease
(15.8%), aortic plaques, aortic valve sclerosis, atrial septal aneurysms, regional myocardial
dyskinesia, dilated left atrium and atrial septal defects. Older patients (> 55 years, n = 291) and
patients with IS had more relevant echocardiographic findings than younger patients or patients
with TIA, respectively (p = 0.002, p = 0.003). The prevalence rates of PFO or ASD were higher in
younger patients (PFO: 26.8% vs. 18.0%, p = 0.005, ASD: 9.6% vs. 4.9%, p = 0.014).
Conclusion: A TEE examination in cryptogenic stroke reveals contributing cardiogenic factors in
about half of all patients. Younger patients had a higher prevalence of PFO, whereas older patients
had more frequently atherosclerotic findings. Therefore, TEE examinations seem indicated in all
patients with cryptogenic stroke – irrespective of age – because of specific therapeutic
consequences.
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Cerebral ischemia is among the most common causes of
hospitalization, morbidity and mortality in western civili-
zations. Stroke databases suggest that despite intensive
evaluation, approximately 40% of all patients suffering
ischemic strokes have no clearly identifiable cause and
15–20% of the ischemic events occur in younger patients
(<55 years). In the literature, however, there is no consen-
sus on the percentage of ischemic strokes caused by cardi-
oembolic events [1].
Interatrial communications (ASD, PFO with and without
atrial septal aneurysms [ASA]) can lead to paradoxical
stroke and increase the risk for recurrent thrombembolic
cerebral events. [2-4].
In an autopsy study, the overall prevalence of a PFO was
27.3%. [5] A meta-analysis has shown that a PFO is more
common in patients younger than < 55 years with sus-
pected cryptogenic stroke than in healthy controls [6].
Hence, a PFO is considered as a risk factor for ischemic
cerebral events in younger patients. In older patients (i.e.
> 55 years), the association between strokes and preva-
lence of a PFO is much weaker [7].
In clinical practice, it is not easy to verify paradoxical
embolism. In current guidelines, there is no consensus on
the clinical relevance of a PFO in cryptogenic stroke and
on the indication for the closure of a PFO after a stroke
[8].
The aim of this study was to determine the prevalence of
echocardiographic findings by TEE in a large number of
patients with cryptogenic cerebral ischemia with a focus
on pre-defined subgroups (age, sex, stroke vs. TIA).
Methods
In this single center retrospective study, 702 consecutive
patients with acute cerebral ischemia were examined by
TEE (1996–2001). All patients underwent neurological
clinical examination, electroencephalogram, cCT or
cMRT, and laboratory tests. All patients had a 12-lead-
ECG, Holter-ECG, extracranial color-coded sonography,
transthoracic echocardiography with no explanations for
cerebral ischemia.
Exclusion criteria were: hemodynamically relevant sten-
oses of the intra- and extracranial arteries, cerebral hemor-
rhage, atrial fibrillation, migraine, epilepsy, intracranial
tumors, acute myocardial infarction in the previous four
weeks, previously diagnosed chronic heart failure and left
ventricular aneurysms and less than 18 years of age.
Ischemic stroke was defined as a cerebrovascular event
with symptoms lasting longer than 24 hours. Diagnosis of
ischemic stroke or TIA was confirmed by a study neurolo-
gist based on clinical syndrome and results of diagnostic
tests, including CT/MRI scans.
Transesophageal echocardiography was performed with a
multiplane probe (5–7 MHz) on a Vivid 5 (TEE probe
MPTE 5MHz 6A, GE Vingmed, Horton, Norway) and a HP
Sonos 5500 (TEE probe HP 21369A; Hewlett-Packard,
Paolo Alto, California, USA).
Before transesophageal echocardiography, intraoral xylo-
caine spray and intravenous midazolam were adminis-
tered according to the requirements of the patient. The
heart rhythm was monitored by ECG during the examina-
tion.
Each TEE examination included the standard views and
measurement of blood velocities in the left atrial append-
age, intravenous administration of contrast agent and Val-
salva manoeuvre to exclude interatrial communications
(according to [9]).
The images were stored digitally and analyzed off-line by
EchoPac PC Dimension (GE Vingmed, Horton Norway)
and additionally on video. Echovist 300 was used as con-
trast medium (Galactose; Schering, Berlin, Germany).
Echovist is approved for the diagnosis of intra-atrial com-
munications.
Written consent was obtained from each patient for the
TEE, and the ethics committee of the Charité University
Hospital approved the protocol.
Statistics
Statistics were calculated by Statgraphics plus (Version 6,
Herndon, Virginia USA). Results are expressed as mean (±
standard deviation). Comparisons of parametric variables
between the responders and the non-responders were cal-
culated by paired Student's t-test. The comparison of
echocardiographic parameters between groups was calcu-
lated by unpaired Whitney-Mann test. Dichotomized data
were analyzed by the Chi2-test. The level of significance
was p ≤ 0.05.
Results
702 consecutive patients were included. 380 (54.1%)
were male, 322 (45.9%) female. 383 (54.6%) of the
patients had an IS and 319 (45.4%) had a TIA. 411
patients were younger than 55 years (58.5%) and 291
patients were older than 55 years (41.5%).
The stroke subgroup was significantly older and had more
frequently pathological TEE findings than the patients suf-
fering from a TIA. (Table 1).Page 2 of 8
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listed in (Table 2). Neither the presence of a PFO (p =
0.053), nor of an ASD (p = 0.65) or an atrial septal aneu-
rysm (p = 0.21) was significantly different in the IS and
TIA groups. However, findings attributable to atheroscle-
rosis (valvular abnormalities including mitral valve calci-
fication, aortic calcification, aortic valve sclerosis, aortic
plaque) were significantly more frequent in the ischemic
stroke group (Table 3).
In the older patients (> 55 years, n = 291, according to
[2,10]) pathological echocardiographic findings were
more frequent (p = 0.0023) than in the younger patients.
The prevalence of a PFO was higher in the younger
patients (< 55 years: n = 78; 26.8%, > 55 years: n = 75;
18.0%, Pearson's Chi square p = 0.005). The frequency of
a ASD was lower in the older patients (< 55 years: n = 28;
9.6%, > 55 years: n = 20; 4.9%, Pearson's Chi square p =
0.014); see Figure 1, for examples see Figure 2, Figure 3
and Figure 4 and Additional file 1, Additional file 2 and
Additional file 3
The most frequent combination of two findings was
PFO+ASA (2.63% male with IS, 2.71% male with TIA,
2.63% female with TIA, 2.71% female with IS).
Discussion
This study is to our knowledge the largest TEE study in
patients with cryptogenic cerebral ischemia allowing the
analysis of the full spectrum of findings and especially the
prevalence of a PFO.
In half of all patients, a possible cardiogenic cause was
identified by TEE. The most frequent finding was a PFO.
The frequency of positive TEE findings that might explain
cerebral ischemia is comparable to previous smaller stud-
ies [11,12].
Cardiogenic causes of ischemic stroke can be divided into
major (annual incidence of embolic events > 1%) and
minor risk factors (annual incidence < 1%) [13]. The
major risk factors are atrial fibrillation (1–12%/year), int-
racardiac thrombi (0–35%), atrial myxoma (30–40%),
mitral valve stenosis (8–14% in sinus rhythm, 31–65%
with concomitant atrial fibrillation), recent myocardial
infarction (1–2%), anticoagulated mechanical heart
valves (1.5–3%), infective endocarditis (12–40%), dilated
cardiomyopathy (4%) and aortic arch atheromatous
plaques (4–16% especially if ≥ 4 mm in diameter, [14]).
The minor risk factors include mitral valve prolapse
(<0.02%) and left ventricular aneurysm (<1%). Rare
causes of cardioembolism include Chiari network,
Lambl's excrescences [15], and valvular abnormalities
[16,17]. Spontaneous echo contrast (SEC) is seen in areas
of blood stasis with a slowly moving, cloud-like swirling
pattern of "smoke" or increased echogenicity recorded in
TEE. However, there is little data on the precise embolic
risk of mitral valve annular calcification, spontaneous
echo contrast, atrial septal aneurysm, and calcific aortic
stenosis [13].
A substantial subset of the cardiogenic factors diagnosed
by TEE could have been found with TTE (in combination
with trans-cranial Doppler) as well. However, there are no
prospective studies showing equivalent diagnostic accu-
racy of TTE compared to TEE in this setting. Despite the
semi-invasivity of TEE, it is still the gold standard for the
detection of inter-atrial communications.
Table 1: Patient characteristics (median, ± SD, n [%])
All (n = 702) Ischemic stroke (n = 383, 54.6%) TIA (n = 319, 45.4%)) p
Age 57.1 (± 15.7) 61.5 (± 12.3) 51.3 (± 16.2) <0.001
Male Sex (%) 380 (54.1%) 222 (57.9%) 158 (49.5%) 0.043
Diabetes mellitus 13.0% 21.2% 7.0% 0.17
Arterial hypertension 39.5% 59.4% 25.6% 0.09
Hyperlipidemia 35.5% 50.0% 25.6% 0.07
Smoker 26.0% 27.6% 25.6% 0.82
Coronary artery disease 14.3% 21.2% 9.3% 0.31
Any pathological echo finding 369 (52.6%) 225 (58.7%) 144 (45.1%) 0.02
Number of pathological findings if any 2.24 2.43 1.92 0.003Page 3 of 8
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Patients with TIA had less frequently a pathological find-
ing in the TEE. This could be due to the fact that the ini-
tially suspected diagnosis "TIA" has a lower specificity
with a broader range of other possible non-vascular etiol-
ogies such as migraine or focal seizures.
Age
We found a higher prevalence of PFO and ASD in the
younger patients (< 55 years). In contrast, Handke [10]
reported that PFO are equally distributed in all age groups
of patients with cryptogenic stroke. Despite these differ-
ences, relevant causes for cerebral ischemia can be identi-
fied in all age-groups. Therefore, a restriction of a TEE
examination to younger patients with TIA/stroke is not
supported by our data.
The current data does not allow a clear recommendation
for PFO closure in patients with cryptogenic stroke. Fur-
ther prospective studies are needed to decide on the clini-
cal advantage of PFO closure, especially in patients > 55
years of age.
Cardioembolic factors – consequences
The TEE findings can have specific therapeutic conse-
quences in all age groups (see table 4). Specifically, as the
therapeutic consequence of LA-appendage thrombus is
oral anticoagulation, its presence should be ruled out
before further treatment is limited to platelet aggregation
inhibition alone [13,18].
PFO-ASA
The association of ischemic stroke and PFO is still contro-
versial: A recent large study in a multiethnic population
did not confirm an association of PFO and the risk for an
ischemic stroke [19]. However, two studies [20,21]have
seen a clear association of PFO and ASA in ischemic
stroke.
The diagnosis of a PFO or ASA depends on experienced
echocardiographers and has – even among experienced
examiners – a high inter- and intra-observer variability
[3]. Clear diagnostic criteria for intra-atrial defects could
reduce the variability [9].
Surgical [22] or percutaneous closure of a PFO is a thera-
peutic strategy with somewhat inconsistent results
[23,24]. The percutaneous closure of a PFO after recurrent
cerebral ischemia is a safe procedure and leads to a reduc-
tion of recurrence rates in the long-term follow-up. Only
in a small number of patients, there was a residual shunt
with subsequent TIA within the first six months after clo-
sure [25]. The recurrent ischemic events in these studies
were attributed to a residual post-procedural shunt.
Hence, improvement of occluder devices may further
reduce the recurrence rates after PFO closure.
Conservative strategies (i.e. antithrombotic therapy) in
patients with a PFO are also associated with comparable
recurrence rates [26]. However, the risks of antithrom-
Table 2: Echocardiographic findings in all patients.
Finding n %
Any echocardiographic finding 369 52.6
Patent Foramen ovale (PFO) 152 21.7
Valvular abnormalities 111 15.8
Aortic plaques 102 14.5
Aortic valve sclerosis 66 9.4
Atrial septal aneurysm 51 7.3
regional myocardial dyskinesia in > 2 segments 50 7.1
Left atrial dilatation 47 6.7
Atrial septal defect 28 4.0
Spontaneous echo contrast (SEC) 18 2.6
Mitral valve prolapse 15 2.1
Valvular vegetations 14 2.0
Aortic valve strands 14 2.0
Intracardial thrombi 13 1.9
mitral valve annulus calcification 10 1.4
Chiari networkt 6 0.9
Aortic valve stenosis 5 0.7
Mitral valve strands 5 0.7
Aortic thrombi 4 0.6
Aortic aneurysm 3 0.4
Prosthetic valve 3 0.43
Left ventricular dilatation 3 0.43
Intracardiac tumor 1 0.14
Mitral valve stenosis 1 0.14Page 4 of 8
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include bleeding and low compliance rates. A randomized
study (PICSS) did not reveal a significant difference in
recurrence rates in medically treated patients with or with-
out a PFO [4]. Especially in younger patients on medical
therapy, the presence of a PFO did not increase the risk of
stroke recurrence [27].
In addition to cardiogenic factors, recently, genetic poly-
morphisms of a variety of genes have been associated with
cryptogenic stroke. However, the degree of association
and the diagnostic relevance of these genetic polymor-
phisms is currently not clear [28].
On the background of our study, we recommend the fol-
lowing diagnostic algorithm for patients with cryptogenic
Table 3: The 10 most frequent findings in the stroke and TIA subgroups
Rank Ischemic stroke (n = 383) TIA (n = 319) P (Chi2 Pearson)
1 PFO (94; 24.5%) PFO (58; 18.2%) 0.053
2 Valvular abnormalities (73; 19.1%) Valvular abnormalities (38; 11.9%) 0.014
3 Aortic calcification (73; 19.1%) Aortic calcification (32; 10.0%) 0.001
4 Aortic plaque (71; 18.5%) Aortic plaque (31; 9.7%) 0.002
5 Aoric valve aclerosis (45; 11.7%) Aoric valve aclerosis (21; 6.6%) 0.029
6 Atrial septal aneurysm (36; 9.4%) Left atrial dilatation (20; 6.3%) LA dilatation: 0.807
7 regional myocardial dyskinesia in > 2 segments (33; 8.6%) regional myocardial dyskinesia in > 2 segments (17; 5.3%) 0.131
8 Left atrial dilatation (27; 7.0%) Atrial septal aneurysm (15; 4.7%) ASA 0.213
9 ASD (17; 4.4%) ASD (11; 3.4%) 0.65
10 SEC(16; 4.2%) Mitral valve prolapse (6; 1.9%)
Presence of PFO and ASD in the patients with cryptogenic stroke (n = 291 < 55 years; n = 411 > 55 years)Figure 1
Presence of PFO and ASD in the patients with cryp-
togenic stroke (n = 291 < 55 years; n = 411 > 55 
years).
TEE image showing a PFO with the clearly visible interatrial communicationFigure 2
TEE image showing a PFO with the clearly visible 
interatrial communication.Page 5 of 8
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tion, electroencephalogram, cCT or cMRT, 12-lead-ECG,
Holter-ECG, extracranial color-coded sonography, tran-
scranial Doppler, transthoracic echocardiography. Only if
these examinations do not reveal a cause for the stroke, a
TEE seems indicated.
Conclusion
In conclusion, in this large study in patients with cryp-
togenic stroke, a TEE reveals in about half of the patients
cardiogenic factors that might explain the stroke. Espe-
cially, the prevalence of a PFO is higher in the younger
patients (< 55 years of age). Therefore, a TEE seems indi-
cated in all patients with cryptogenic stroke – irrespective
of age – because of specific therapeutic consequences.
Limitations
This study was observational. The quality of observational
studies seems to be comparable to randomized controlled
trials [29,30]. There was no follow-up of the patients con-
cerning recurrence of cerebral ischemia or mortality.
We did not analyze the prevalence of abnormal TEE find-
ings in single-vessel and lacunar strokes in comparison to
Table 4: TEE findings in patients with ischemic stroke and their possible therapeutic consequences.
TEE finding Possible therapeutic consequence
PFO and ASD ASS, anticoagulation, operative or interventional device closure
aortic plaques ASS, statin therapy
reduced LVEF oral anticoagulation, ASS, coronary angiography, heart failure therapy
left atrial dilatation further cardiological work-up
Spontaneous echo contrast search for intermittent atrial fibrillation, oral anticoagulation
left atrial thrombus anticoagulation, operation
thoracic aneurysm of the aorta echo control, operation
mitral valve prolapse antiarrhythmic therapy, echo follow-up, anticoagulation
aortic/mitral valve stenosis timing of valve replacement
LA-appendage thrombus oral anticoagulation
TEE showing the transfer of EchoVist from the right to the left atrium during V lsalva's man euvreFigure 3
TEE showing the transfer of EchoVist from the right 
to the left atrium during Valsalva's manoeuvre.
TEE image showing an ASD and the color coded Dopper vis-ualizing the left-to-right shuntFigure 4
TEE image showing an ASD and the color coded 
Dopper visualizing the left-to-right shunt.Page 6 of 8
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(1996–2001). Currently, the indication for a TEE in cryp-
togenic stroke is more selective.
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